Related Experiment Video

Updated: Jun 13, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

[Angiotensin II receptor blocker add-on therapy for low cardiac output in decompensated heart failure]

Marcelo E Ochiai1, Antonio C P Barretto, Juliano N Cardoso

  • 1Hospital Auxiliar de Cotoxó do Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, USP, São Paulo, SP, Brasil. marcelo.ochiai@incor.usp.br

Arquivos Brasileiros De Cardiologia
|April 30, 2010
PubMed

Insights

Adding angiotensin II receptor blockers (ARB) to angiotensin-converting enzyme inhibitors (ACEI) significantly improved the ability to withdraw dobutamine in patients with advanced decompensated heart failure. This combination therapy offers a promising strategy for managing severe heart failure.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) decompensation involves intense renin-angiotensin-aldosterone system activation.
  • Angiotensin-converting enzyme inhibitors (ACEI) alone may not fully block this system.
  • Angiotensin II receptor blockers (ARB) can be beneficial when inotropic support is needed.

Purpose of the Study:

  • To evaluate the efficacy of combining ARB and ACEI for dobutamine withdrawal in advanced decompensated HF.
  • To assess the impact of ARB-ACEI association on reducing intravenous inotropic support dependency.

Main Methods:

  • A case-control study included 24 patients with advanced HF on dobutamine for over 15 days.
  • Patients had failed previous dobutamine withdrawal attempts and were on optimized ACEI.
  • 12 patients received additional ARB, while 12 served as controls; outcome was successful dobutamine withdrawal.

Main Results:

  • Successful dobutamine withdrawal occurred in 67.7% of the ARB group versus 16.7% in the control group.
  • The odds ratio for successful withdrawal with ARB was 10.0 (p=0.02).
  • Worsening renal function was comparable between groups (42% vs. 67%, p=0.129).

Conclusions:

  • The ARB-ACEI combination shows potential for successful dobutamine withdrawal in advanced decompensated HF.
  • Renal function impact was similar between groups in this pilot study.
  • Further research is needed to confirm these findings and clarify the role of ARB-ACEI therapy.
Abstract

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...